Etiologies of acute liver failure

Current Opinion in Critical Care

Volumn 14, Issue 2, 2008, Pages 198-201

  Lee, William M ^a   Seremba, Emmanuel ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Chemotherapy; Drug induced liver injury; Fulminant hepatic failure

Indexed keywords

ABACAVIR; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BETA INTERFERON; BROMFENAC; DICLOFENAC; FLUCLOXACILLIN; ISONIAZID; NELFINAVIR; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN; THALIDOMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER CHEMOTHERAPY; DRUG INDUCED DISEASE; HEPATITIS B; HEPATITIS E; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INNATE IMMUNITY; LIVER FAILURE; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; PATHOGENESIS; REVIEW; UNSPECIFIED SIDE EFFECT;

ACETAMINOPHEN; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-RETROVIRAL AGENTS; HEPATITIS, VIRAL, HUMAN; HUMANS; INFLAMMATION; LIVER FAILURE, ACUTE; PROGNOSIS; RISK FACTORS;

EID: 41849083084     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e3282f6a420     Document Type: Review

References (45)

1. Ostapowicz GA, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:945-954.
2. Bernal W. Changing patterns of causation and the use of transplantation in the United Kingdom. Sem Liver Dis 2003; 23:227-237.
3. Ostapowicz G, Lee WM. Acute liver failure: the Western experience. J Gastroenterol Hepatol 2000; 15:480-488.
4. Escorsell A, Mas A, de la Mata M, and the Spanish Group for the Study of Acute Liver Failure. Acute liver failure in Spain: analysis of 267 cases. Liver Transpl 2007; 13:1389-1395. This paper discusses the overall etiologies of ALF in Spain, possibly representative of at least part of Europe.
5. Polson J, Lee WM. Etiologies of acute liver failure: location, location, location. Liver Transplant 2007; 13:1364-1365.
6. Larson AM, Fontana RJ, Davern TJ, et al., and the ALFSG.. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study. Hepatology 2005; 42:1367-1372.
7. Davern TJ II, James LP, Hinson JA, et al., and the ALFSG. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006; 130:687-694.
8. James LP, Alonso EM, Hynan LS, et al., and the Pediatric Acute Liver Failure Study Group. Detection of acetaminophen-protein adducts in children with acute liver failure of indeterminate cause. Pediatrics 2006; 118:676-681.
9. Hawton K, Townsend E, Deeks J, et al. Effects of legislation restricting packsizes of paracetamol and salicylate poisoning in the United Kingdom before and after study. Br Med J 2001; 322:1203-1207.
10. Sheen C, Dillon J, Bateman D, et al. Paracetamol pack size restriction: the impact on paracetamol poisoning and over-the-counter supply of paracetamol, aspirin and ibuprofen. Pharmacoepidemiol and Drug Saf 2002; 11:329-331.
11. Lee WM. Acute liver failure in the United States. Semin Liv Dis 2003; 23:217-226.
12. Department of Health and Human Services, Food and Drug Administration. 21 CFR Parts 201 and 343 [Docket No. 1977N-0094L] RIN 0910-AF36 Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; proposed amendment of the tentative final monograph; required warnings and other labeling; 2006. Available at: http://www.accessdata.fda.gov/ scripts/oc/ohrms/frbydocket.cfm.
13. Lee WM. Acetaminophen hepatotoxicity: Changing perceptions of a social/medical issue. Hepatology 2007; 6:966-960.
14. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin Liver Dis 2002; 22:137-144.
15. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 2005; 4:489-499.
16. Chang CY, Schiano TD. Drug-induced hepatotoxicity. Aliment Pharm Therapeut 2007; 25:1135-1151. Short overview of the current drugs involved in causing liver injury.
17. Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006; 354:731-739.
18. Clay KD, Hanson JS, Pope SD, et al. Brief communication: severe hepatotoxicity of telithromycin: three case reports and literature review. Ann Intern Med 2006; 144:415-420.
19. Wassel R, Brinker A. An evaluation of hepatic events associated with telithromycin. In: Division of Drug Risk Evaluation Office of Surveillance and Epidemiology. Briefing Document; 2006. pp. 23-50. Available from: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4266b1-00-index.htm.
20. Graham DJ. Telithromycin and acute liver failure. Letter to the Editor. New Engl J Med 2006; 355:2260-2261.
21. Ross DB. The FDA and the case of Ketek. New Engl J Med 2007; 356:1601-1603.
22. Yew WW, Leung CC. Antituberculosis drugs and hepatotoxicity. Respirology 2006; 11:699-707.
23. Smink R, van Hoek B, Ringers J, et al. Risk factors of acute hepatic failure during antituberculosis treatment: two cases and literature review. Neth J Med 2006; 64:377-384.
24. Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Drug-induced liver injury. Clin Liver Dis 2007; 11:563-575. This article discusses nonsteroidal anti-inflammatory drugs and the genetic basis for their toxicity.
25. Fontana RJ, McCashland TM, Benner KG, et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. Liver Transplant Surg 1999; 5:480-484.
26. Lapeyre-Mestre M, Rueda de Castro AM, Bareille M-P, et al. Nonsteroidal antiinflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fund Clin Pharmacol 2006; 20:391-395.
27. Daly AK, Aithal GP, Leathart JBS, et al. Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8 and ABCC2 genotypes. Gastroenterology 2007; 137:272-281. This paper elucidates several important loci for nonsteroidal anti-inflammatory drug injury polymorphisms.
28. Buyse S, Vibert E, Sebagh M, et al. Liver transplantation for fulminant hepatitis related to nevirapine therapy. Liver Transpl 2006; 12:18680-18682.
29. Mira JA, Macias J, Giron-Gonzalez JA, et al. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2006; 58:140-146.
30. Nunez M. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. J Hepatol 2006; 44:S132-S139.
31. Sidiq H, Ankoma-Sey V. HIV-related disease: infection vs. drugs. Gastroenterol Clin N Am 2006; 35:487-505.
32. Jain MK, Parekh NK, Hester J, Lee WM. Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs. AIDS Patient Care STDS 2006; 20:817-822.
33. Rodriguez-Frias EA, Lee WM. Cancer chemotherapy I: Hepatocellular injury. Clin Liver Dis 2007; 11:641-662.
34. Rodriguez-Frias EA, Lee WM. Cancer chemotherapy II: Atypical hepatic injuries. Clin Liver Dis 2007; 11:663-676.
35. Hamadani M, Benson DM, Copelan EA. Thalidomide-induced fulminant hepatic failure. Mayo Clin Proc 2007; 82:638-639.
36. Montero JL, Cerezo A, Fraga E, et al. Acute liver failure in a patient with multiple sclerosis treated with interferon-beta [case reports. letter]. Multiple Sclerosis 2007; 13:820.
37. Taylor RM, Davern TJ, Munoz S, et al. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology 2006; 44:1589-1597.
38. Sookoian S. Liver disease during pregnancy: acute viral hepatitis. Ann Hepatol 2006; 5:231-236.
39. Jilani N, Das BC, Husain SA, et al. Hepatitis E virus infection and fulminant hepatic failure during pregnancy. J Gastroenterol Hepatol 2007; 22:676-682.
40. Lee WM, Brown KE, Young NS, et al., and the Acute Liver Failure Study Group. Brief report: No evidence for hepatitis E or parvovirus B19 Infection in patients with acute liver failure. Dig Dis Sci 2006; 51:1712-1715.
41. Nakazawa H, Ito T, Makashima H, et al. Adenovirus fulminant hepatic failure: disseminated adenoviral disease after unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia. Intern Med 2006; 45:975-980.
42. Ikeda K, Shiga Y, Takahashi A, et al. Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment. Leuk Lymphoma 2006; 47:155-157.
43. Yeo W, Chan PKS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62:299-307.
44. Squires RH Jr, Shneider BL, Bucuvalas J, et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 2006; 148:652-658.
45. William Bernal W, Ma Y, Smith HM, et al. The significance of autoantibodies and immunoglobulins in acute liver failure: A cohort study. J Hepatol 2007; 47:664-670.